RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models

Agents that inhibit estrogen production, such as aromatase inhibitors or those that directly block estrogen receptor (ER) activity, such as selective estrogen receptor modulators and selective estrogen receptor degraders, are routinely used in the treatment of ER-positive breast cancers. However, al...

Descripción completa

Detalles Bibliográficos
Autores principales: Garner, Fiona, Shomali, Maysoun, Paquin, Dotty, Lyttle, C. Richard, Hattersley, Gary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2015
Materias:
Preclinical Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560273/
https://www.ncbi.nlm.nih.gov/pubmed/26164151
http://dx.doi.org/10.1097/CAD.0000000000000271

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560273/
https://www.ncbi.nlm.nih.gov/pubmed/26164151
http://dx.doi.org/10.1097/CAD.0000000000000271

Ejemplares similares